InsidersTradesSigma
Track the Venus Concept Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Venus Concept Inc. has recorded 43 reports. Market capitalisation: €578k. The latest transaction was reported on 30 March 2026 (Acquisition). Among the most active insiders: Serafino Domenic. All data is free.
43
Insider Decl.
n/a
Thresholds
€892,013
25 ops.
Buy Volume
€684,578
11 ops.
Sell Volume
65Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 March 2026
Declarations43 total
37,500,000 shares@ €0.0346Common StockSEC:0001193125-26-132846:0
Canonical exit: 24 Jun 2026 (T+90)
42,768 shares@ US$0.308535.3% of flowCommon SharesSEC:0000912282-24-000855:0
50,901 shares@ US$0.525210.6% of flowCommon Stock, $0.0001 par value per shareSEC:0000919574-24-005769:0
22,301 shares@ US$0.64495.7% of flowCommon Stock, $0.0001 par value per shareSEC:0000919574-24-005707:0
172,314 shares@ US$1.203483.7% of flowCommon Stock, $0.0001 par value per shareSEC:0000919574-24-003602:0
834 sharesCommon StockSEC:0001362118-23-000050:0
12,500 sharesCommon StockSEC:0001362118-23-000018:0
25,000 sharesCommon StockSEC:0001362118-23-000017:0
18,750 sharesCommon StockSEC:0001362118-23-000024:0
18,750 sharesCommon StockSEC:0001362118-23-000019:0
37,500 sharesCommon StockSEC:0001362118-23-000023:0
51,428 shares@ US$0.26637.0% of flowCommon SharesSEC:0001567619-22-021055:0
51,428 shares@ US$0.196527.7% of flowCommon SharesSEC:0001567619-22-020887:0
129,309 sharesCommon StockSEC:0001567619-22-020883:0
250,000 shares@ US$0.20100.0% of flowCommon StockSEC:0001567619-22-020781:0
Canonical exit: 16 Feb 2023 (T+90)
60,000 shares@ US$0.229.1% of flowCommon SharesSEC:0001567619-22-020790:0
Canonical exit: 19 Feb 2023 (T+90)
1,250,000 shares@ US$0.20100.0% of flowCommon StockSEC:0001567619-22-020779:0
Canonical exit: 16 Feb 2023 (T+90)
250,000 shares@ US$0.2066.8% of flowCommon StockSEC:0001567619-22-020783:0
Canonical exit: 16 Feb 2023 (T+90)
30,000 shares@ US$0.577622.4% of flowCommon SharesSEC:0001567619-22-017610:0
Canonical exit: 15 Dec 2022 (T+90)
12,782 shares@ US$0.7106100.0% of flowCommon SharesSEC:0001567619-22-017331:0
Canonical exit: 11 Dec 2022 (T+90)
37,500 shares@ US$0.33923.2% of flowCommon SharesSEC:0001362118-22-000059:0
Canonical exit: 28 Nov 2022 (T+90)
40,000 shares@ US$0.6434.14% mcap100.0% of flowCommon SharesSEC:0001567619-22-011758:0
Canonical exit: 22 Aug 2022 (T+90)
65,000 shares@ US$0.757.97% mcap12.0% of flowCommon SharesSEC:0001567619-22-011520:0
Canonical exit: 18 Aug 2022 (T+90)
10,000 shares@ US$0.851.39% mcap6.3% of flowCommon SharesSEC:0001567619-22-011129:0
Canonical exit: 15 Aug 2022 (T+90)
20,000 shares@ US$1.354.14% mcap18.8% of flowCommon SharesSEC:0001567619-21-022355:0
Canonical exit: 16 Mar 2022 (T+90)
25 of 43 declarations
关于 Venus Concept Inc.
Venus Concept Inc. 是一家在美国上市的医疗技术公司，在纳斯达克交易，股票代码为 VERO。尽管其主要行政办公室位于安大略省多伦多，但该公司是美国特拉华州的一家公司，其商业足迹遍布全球。该公司成立于 2002 年 11 月 22 日，其业务围绕微创和非侵入性医疗美容技术，以及头发修复解决方案和相关服务而建立。([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000143774925009968/vero20241231_10k.htm)) Venus Concept 模式的核心是向医生、皮肤科医生、整形外科医生和美容诊所销售的医疗设备和相关服务组合。历史上，该公司专注于基于能量的美容平台和机器人头发修复系统，并辅以培训、临床教育和实践增长服务。其最著名的技术之一是 ARTAS 系统，这是一个机器人平台，旨在协助医生完成头发修复手术的关键步骤，包括毛囊提取和植发。此外，该公司还提供结构化融资和商业计划，特别是 Venus Prime，它取代了其传统的北美订阅模式，为客户提供了支付灵活性和技术升级路径。([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000143774925009968/vero20241231_10k.htm)) 从竞争角度来看，Venus Concept 在一个专业但竞争激烈的领域运营，该领域位于美容医学、资本设备、循环融资和实践支持的交汇处。其差异化在于提供集设备、耗材、软件支持的工作流程、内部融资和业务发展支持于一体的综合产品。管理层披露，截至 2024 年 12 月 31 日，该公司直接在 12 个国际市场运营，在美国、加拿大、日本、墨西哥、西班牙、德国、澳大利亚、中国、香港和以色列设有办事处。这种地域覆盖使该业务具有重要的国际影响力，尽管北美仍然具有战略重要性。([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000114036125016519/ny20045858x2_ars.pdf?utm_source=openai)) 最近的发展对投资者来说很重要。2025 年 6 月，Venus Concept 宣布了一项最终协议，以 20 million 美元的价格出售其 Venus Hair 业务，此举旨在加强资产负债表并为战略增长计划提供资金。2025 年 7 月，该公司还宣布了一项 6.5 million 美元的债转股交易，进一步减少了未偿债务。最值得注意的是，2025 年 11 月，Venus Concept 获得了 FDA 510(k) 批准，用于 Venus NOVA，该产品被描述为用于非侵入性身体和皮肤治疗的下一代多应用平台。总而言之，这些行动表明该公司仍处于转型模式，平衡重组、去杠杆化和产品创新。([ir.venusconcept.com](https://ir.venusconcept.com/news-releases/news-release-details/venus-concept-announces-definitive-agreement-sell-venus-hair/?utm_source=openai))
